An injectable thermosensitive polymeric hydrogel for sustained release of Avastin1 to treat posterior segment disease

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 375-383

  Xie, Binbin ^a   Jin, Ling ^a   Luo, Zichao ^a   Yu, Jing ^a   Shi, Shuai ^a   Zhang, Zhaoliang ^a   Shen, Meixiao ^a   Chen, Hao ^a   Li, Xingyi ^a   Song, Zongming ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Avastin ; Posterior segment disorder; Sustained release; Thermosensitive hydrogel

Indexed keywords

BEVACIZUMAB; MACROGOL; POLYGLACTIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; HYDROGEL; LACTIC ACID; MACROGOL DERIVATIVE; POLYESTER; POLYETHYLENE GLYCOL-POLY(LACTIDE-CO-GLYCOLIDE); POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG CLEARANCE; ELECTROPHYSIOLOGY; EYE DISEASE; HEAT SENSITIVITY; HYDROGEL; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RAT; RETINA; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; VITREOUS BODY; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; INJECTION; METABOLISM; PROCEDURES; TEMPERATURE;

ANIMALS; BEVACIZUMAB; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYDROGEL; HYDROGELS; INJECTIONS; LACTIC ACID; MALE; POLYESTERS; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; RATS; RETINA; TEMPERATURE; VITREOUS BODY;

EID: 84935017797     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.071     Document Type: Article

References (33)

1. Agrawal, A. K., Das, M., Jain, S., 2012. In situ gel systems as' smart'carriers for sustained ocular drug delivery. Expert Opin. Drug Del. 9, 383-402.
2. Almeida, H., Amaral, M. H., Lobao, P., Lobo, J. M., 2014. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov. Today 19, 400-412.
3. Ambati, J., Canakis, C. S., Miller, J. W., Gragoudas, E. S., Edwards, A., Weissgold, D. J., Kim, I., Delori, F. C., Adamis, A. P., 2000. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41, 1181-1185.
4. Arsiwala, A., Desai, P., Patravale, V., 2014. Recent advances in micro/nanoscale biomedical implants. J. Control. Release 189, 25-45.
5. Bochot, A., Fattal, E., 2012. Liposomes for intravitreal drug delivery: a state of the art. J. Control. Release 161, 628-634.
6. Casolaro, M., Casolaro, I., Lamponi, S., 2012. Stimuli-responsive hydrogels for controlled pilocarpine ocular delivery. Eur. J. Pharm. Biopharm. 80, 553-561.
7. Chen, X., Li, X., Zhou, Y., Wang, X., Zhang, Y., Fan, Y., Huang, Y., Liu, Y., 2011. Chitosanbased thermosensitive hydrogel as a promising ocular drug delivery system: preparation, characterization, and in vivo evaluation. J. Biomater. Appl. 27, 391-402.
8. Dai, X., Han, J., Qi, Y., Zhang, H., Xiang, L., Lv, J., Li, J., Deng, W. T., Chang, B., Hauswirth, W. W., Pang, J. J., 2014. AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice. Invest. Ophthalmol. Vis. Sci. 55, 1724-1734.
9. Edelhauser, H. F., Rowe-Rendleman, C. L., Robinson, M. R., Dawson, D. G., Chader, G. J., Grossniklaus, H. E., Rittenhouse, K. D., Wilson, C. G., Weber, D. A., Kuppermann, B. D., 2010. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest. Ophthalmol. Vis. Sci. 51, 5403-5420.
10. El-Kamel, A. H., 2002. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241, 47-55.
11. Fitzpatrick, S. D., Mazumder, J., Muirhead, B., Sheardown, H., 2012. Development of injectable, resorbable drug-releasing copolymer scaffolds for minimally invasive sustained ophthalmic therapeutics. Acta Biomater. 8, 2517-2528.
12. Gadjanski, I., Williams, S. K., Hein, K., Sattler, M. B., Bahr, M., Diem, R., 2011. Correlation of optical coherence tomography with clinical and histopathological findings in experimental autoimmune uveoretinitis. Exp. Eye Res. 93, 82-90.
13. Gao, Y., Ren, F., Ding, B., Sun, N., Liu, X., Ding, X., Gao, S., 2011. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. J. Drug Target. 19, 516-527.
14. Gao, Y., Sun, Y., Ren, F., Gao, S., 2010. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev. Ind. Pharm. 36, 1131-1138.
15. Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., 2012. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537-2548.
16. Jeong, B., Kim, S. W., Bae, Y. H., 2002. Thermosensitive sol-gel reversible hydrogels. Adv. Drug Deliv. Rev. 54, 37-51.
17. Kaur, I. P., Kakkar, S., 2014. Nanotherapy for posterior eye diseases. J. Control. Release 193, 100-112.
18. Li, X., Li, L. Zhang, Chen, Z., 2013a. An overview on pharmacokinetics, disposition, and safety of nanoparticles in ocular applications. Curr. Drug Metab. 14, 857-862.
19. Li, X., Zhang, Z., Chen, H., 2013b. Development and evaluation of fast forming nanocomposite hydrogel for ocular delivery of diclofenac. Int. J. Pharm. 448, 96-100.
20. Li, X., Zhang, Z., Li, J., Sun, S., Weng, Y., Chen, H., 2012. Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 4, 4667-4673.
21. Liu, X., Shen, M., Huang, S., Leng, L., Zhu, D., Lu, F., 2014. Repeatability and reproducibility of eight macular intra-retinal layer thicknesses determined by an automated segmentation algorithm using two SD-OCT instruments. PLoS One 9, e87996.
22. Ma, W. D., Xu, H., Wang, C., Nie, S. F., Pan, W. S., 2008. Pluronic F127-g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int. J. Pharm. 350, 247-256.
23. Mahmoud, A. A., El-Feky, G. S., Kamel, R., Awad, G. E. A., 2011. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int. J. Pharm. 413, 229-236.
24. Meyer, C. H., Krohne, T. U., Holz, F. G., 2011. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0mg of bevacizumab in humans. Retina 31, 1877-1884.
25. Miyake, T., Sawada, O., Kakinoki, M., Sawada, T., Kawamura, H., Ogasawara, K., Ohji, M., 2010. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest. Ophth. Vis. Sci. 51, 1606-1608.
26. Mundada, A. S., Avari, J. G., 2009. In situ gelling polymers in ocular drug delivery systems: a review. Crit. Rev. Ther. Drug Carrier Syst. 26, 85-118.
27. Park, M.-R., Chun, C., Ahn, S.-W., Ki, M.-H., Cho, C.-S., Song, S.-C., 2010. Sustained delivery of human growth hormone using a polyelectrolyte complex-loaded thermosensitive polyphosphazene hydrogel. J Control. Release 147, 359-367.
28. Souza, J. G., Dias, K., Pereira, T. A., Bernardi, D. S., Lopez, R. F. V., 2014. Topical delivery of ocular therapeutics: carrier systems and physical methods. J. Pharm. Pharmacol. 66, 507-530.
29. Spataro, G., Malecaze, F., Turrin, C.-O., Soler, V., Duhayon, C., Elena, P.-P., Majoral, J.-P., Caminade, A.-M., 2010. Designing dendrimers for ocular drug delivery. Eur. J. Med. Chem. 45, 326-334.
30. Theodossiadis, P. G., Liarakos, V. S., Sfikakis, P. P., Vergados, I. A., Theodossiadis, G. P., 2009. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am. J. Ophthalmol. 147, 825-830.e1.
31. Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., Alany, R. G., 2011. Drug delivery to the posterior segment of the eye. Drug Discov. Today 16, 270-277.
32. Turturro, S. B., Guthrie, M. J., Appel, A. A., Drapala, P. W., Brey, E. M., Perez-Luna, V. H., Mieler, W. F., Kang-Mieler, J. J., 2011. The effects of cross-linked thermoresponsive PNIPAAm-based hydrogel injectionon retinal function. Biomaterials 32, 3620-3626.
33. Yu, J., Xu, X. Yao, F. Luo, Z. Jin, L. Xie, B. Shi, S. Ma, H. Li, Chen, X., 2014. In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. Int. J. Pharm. 470, 151-157.